SLC5A2 and type 2 diabetes mellitus: A meta-analysis of cardiovascular outcome trials by McGuire et al. reported a 38% relative risk reduction in kidney outcomes with SGLT2-i inhibition among patients with T2DM at elevated cardiovascular risk, regardless of underlying ASCVD status [16].